Microsoft shares jump after fourth-quarter earnings beat on AI-fueled cloud growth
PARIS, FRANCE AND EASTLEIGH AND MANCHESTER, UK - Novacyt (EPA:ALNOV) S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), a global molecular diagnostics firm, disclosed today that its non-trading subsidiary, Lab 21 Healthcare Ltd, has been charged with health and safety violations by the UK's Health and Safety Executive (HSE). The allegations are connected to the management of biological agents at a former Lab 21 facility in Axminster, Devon.
The implicated site was acquired from Omega Diagnostics Ltd as part of Lab 21's purchase of Omega's Infectious Diseases business on June 28, 2018. The activities under scrutiny are no longer part of Novacyt's current operations. An initial hearing regarding these charges is scheduled to take place at a Magistrates' Court on March 18, 2025.
Novacyt, with its headquarters in France and additional offices in the UK, Singapore, the US, and Canada, operates in the field of genomic medicine, offering an array of molecular assays and services. The company's business segments include Clinical, Instrumentation, and Research Use Only, catering to human health, animal health, and environmental sectors.
The forthcoming court proceedings will determine the implications of these charges for Lab 21 and potentially Novacyt. The company has announced that it will provide further updates following the legal case's resolution.
This news comes as part of a statement released by Novacyt and is based on a press release statement. The information is factual, and the company is awaiting the outcome of the legal process.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.